Want to see HK:2407 full AI Analyst Report?
2407 Stock Chart & Stats
HK$7.64
-HK$0.07(-0.81%)
At close: 4:00 PM EST
HK$7.64
-HK$0.07(-0.81%)
Day’s Range― - ―
52-Week RangeHK$4.40 - HK$9.99
Previous CloseN/A
Volume488.20K
Average Volume (3M)147.22K
Market Cap
HK$650.71M
Enterprise ValueHK$1.28K
Total Cash (Recent Filing)HK$440.94M
Total Debt (Recent Filing)HK$507.37M
Price to Earnings (P/E)5.7
Beta0.61
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.82%
Share Statistics
EPS (TTM)0.66
Shares Outstanding147,887,860
10 Day Avg. Volume84,250
30 Day Avg. Volume147,220
Financial Highlights & Ratios
PEG Ratio2.35
Price to Book (P/B)0.64
Price to Sales (P/S)0.78
P/FCF Ratio9.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.22
Revenue Forecast (FY)HK$1.72B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilizationLower leverage and a stronger equity base improve financial resilience and reduce balance-sheet risk. This gives Gaush Meditech more flexibility to fund operations and absorb industry volatility than during its stressed 2020–2021 period.
Positive Free Cash FlowPositive operating and free cash flow indicate that the business is converting a substantial portion of reported earnings into cash. This supports reinvestment, debt management and shareholder returns, despite historical variability in cash conversion.
Underlying ProfitabilityThe company remains profitable with a substantial gross margin, suggesting its medical-device activities retain economic value and pricing capacity. Continued positive earnings provide an operating base from which margins and growth could recover over time.
Bears Say
Revenue ContractionRecent revenue contraction points to softer demand, pricing pressure or execution challenges. If sustained, lower sales would limit operating leverage, make fixed costs harder to absorb and constrain the company’s ability to expand earnings.
Margin Compression And Earnings VolatilityThe sharp change in profitability demonstrates that earnings remain sensitive to operating conditions and cost pressures. Margin recovery is not established, and past losses increase uncertainty around the durability of current earnings power.
Inconsistent Cash ConversionUneven conversion of profits into cash reduces confidence in the persistence of reported earnings and can complicate capital allocation. The company may need to manage working capital and investment carefully to sustain recent cash generation.
Gaush Meditech Ltd. News
2407 FAQ
What was Gaush Meditech Ltd.’s price range in the past 12 months?
Gaush Meditech Ltd. lowest stock price was HK$4.40 and its highest was HK$9.99 in the past 12 months.
What is Gaush Meditech Ltd.’s market cap?
Gaush Meditech Ltd.’s market cap is HK$650.71M.
When is Gaush Meditech Ltd.’s upcoming earnings report date?
Gaush Meditech Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 3 days.
How were Gaush Meditech Ltd.’s earnings last quarter?
Gaush Meditech Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.441 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Gaush Meditech Ltd. overvalued?
According to Wall Street analysts Gaush Meditech Ltd.’s price is currently Overvalued.
Does Gaush Meditech Ltd. pay dividends?
Gaush Meditech Ltd. pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 6.82%. See more information on Gaush Meditech Ltd. dividends here
What is Gaush Meditech Ltd.’s EPS estimate?
Gaush Meditech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gaush Meditech Ltd. have?
Gaush Meditech Ltd. has 147,887,860 shares outstanding.
What happened to Gaush Meditech Ltd.’s price movement after its last earnings report?
Gaush Meditech Ltd. reported an EPS of HK$0.441 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.095%.
Which hedge fund is a major shareholder of Gaush Meditech Ltd.?
Currently, no hedge funds are holding shares in HK:2407
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gaush Meditech Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.77%
12-Months-Change
Fundamentals
Return on Equity
6.82%
Trailing 12-Months
Asset Growth
7.02%
Trailing 12-Months
Company Description
Gaush Meditech Ltd.
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.
Technical Analysis
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―








